文献速递乳腺癌放疗

乳腺癌调强放疗同步整合补量局部控制非劣效且毒性相当:IMRT-MC2 III期试验5年结果

Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-05-26

IMRT-MC2前瞻性多中心III期试验将502例乳腺癌患者随机分组,比较常规分割调强放疗同步整合补量(IMRT-SIB)与三维适形放疗序贯补量的辅助放疗效果。中位随访62个月后,IMRT-SIB组5年局部控制率非劣效于对照组(98.7% vs 98.3%,HR 0.582,95%CI 0.119-2.375,P=0.4595),总生存、无病生存、无远处病生存及晚期毒性和美容评估均无显著差异。

要点

  • IMRT-SIB组5年局部控制率98.7%非劣效于对照组98.3%(HR 0.582,95%CI 0.119-2.375)。
  • 两组5年总生存、无病生存、无远处病生存及晚期毒性、美容评估均无显著差异。
  • 常规分割IMRT-SIB辅助放疗在乳腺癌中安全有效,局部控制非劣效于三维适形放疗序贯补量。

核心结论

  • 5年结果表明,常规分割同步整合补量放疗对乳腺癌患者安全有效,局部控制非劣效于三维适形放疗序贯补量。

研究设计与样本

  • IMRT-MC2为前瞻性多中心III期随机试验(NCT01322854),2011年至2015年间共随机分配502例患者。
  • 比较常规分割调强放疗同步整合补量与三维适形放疗序贯补量的辅助乳腺癌放疗。
  • 分析中位随访62个月的5年晚期毒性、总生存、无病生存、无远处病生存、美容评估(哈佛量表)及局部控制(非劣效界值HR 3.5)。

主要发现

  • IMRT-SIB组5年局部控制率98.7% vs 对照组98.3%(HR 0.582,95%CI 0.119-2.375,P=0.4595),非劣效成立。
  • 5年总生存率97.1% vs 98.3%(HR 1.235,95%CI 0.472-3.413,P=0.6697),无显著差异。
  • 5年无病生存率95.8% vs 96.1%(HR 1.130,95%CI 0.487-2.679,P=0.7758),无显著差异。
  • 5年无远处病生存率97.0% vs 97.8%(HR 1.667,95%CI 0.575-5.434,P=0.3601),无显著差异。
  • 5年后晚期毒性评估和美容评估显示两组间无显著差异。

关键数值与推荐

  • 局部控制非劣效界值设定为风险比(HR)3.5。
  • IMRT-SIB组5年局部控制率98.7% vs 对照组98.3%(HR 0.582,95%CI 0.119-2.375,P=0.4595)。
  • 5年总生存率97.1% vs 98.3%(HR 1.235,95%CI 0.472-3.413,P=0.6697)。
  • 5年无病生存率95.8% vs 96.1%(HR 1.130,95%CI 0.487-2.679,P=0.7758)。
  • 5年无远处病生存率97.0% vs 97.8%(HR 1.667,95%CI 0.575-5.434,P=0.3601)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The IMRT-MC2 trial was conducted to demonstrate the noninferiority of conventionally fractionated intensity modulated radiation therapy with a simultaneous integrated boost to 3-dimensional conformal radiation therapy with a sequential boost for adjuvant breast radiation therapy. METHODS AND MATERIALS: A total of 502 patients were randomized between 2011 and 2015 for the prospective, multicenter, phase III trial (NCT01322854). Five-year results of late toxicity (late effects normal tissue task force-subjective, objective, management, and analytical), overall survival, disease-free survival, distant disease-free survival, cosmesis (Harvard scale), and local control (noninferiority margin at hazard ratio [HR] of 3.5) were analyzed after a median follow-up of 62 months. RESULTS: The 5-year local control rate for the intensity modulated radiation therapy with simultaneous integrated boost arm was non-inferior to the control arm (98.7% vs 98.3%, respectively; HR, 0.582; 95% CI, 0.119-2.375; P = .4595). Furthermore, there was no significant difference in overall survival (97.1% vs 98.3%, respectively; HR, 1.235; 95% CI, 0.472-3.413; P = .6697), disease-free survival (95.8% vs 96.1%, respectively; HR, 1.130; 95% CI, 0.487-2.679; P = .7758), and distant disease-free survival (97.0% vs 97.8%, respectively; HR, 1.667; 95% CI, 0.575-5.434; P = .3601). After 5 years, late toxicity evaluation and cosmetic assessment further showed no significant differences between treatment arms. CONCLUSIONS: The 5-year results of the IMRT-MC2 trial provide strong evidence that the application of conventionally fractionated simultaneous integrated boost irradiation for patients with breast cancer is both safe and effective, with noninferior local control compared with 3-dimensional conformal radiation therapy with sequential boost.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Forster T, Köhler C, Dorn M, et al. Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37244626. doi:10.1016/j.ijrobp.2023.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。